REVIEW
Temozolomide in aggressive pituitary adenomas and carcinomas
Leon D. OrtizI, Luis V. SyroII,
, Bernd W. Scheithauer (in memoriam)III, Fabio RotondoIV, Humberto UribeV, Camilo E. FadulVI, Eva HorvathIV, Kalman KovacsIV
Corresponding author
I Instituto de Cancerologia, Clinica Las Americas, Division of Neuro-oncology, Medellin, Colombia.
II Hospital Pablo Tobon Uribe and Clinica Medellin, Department of Neurosurgery, Medellin, Colombia.
III Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, Minnesota, USA.
IV University of Toronto, St Michael's Hospital, Department of Laboratory Medicine, Toronto, Ontario, Canada.
V Clinica SOMA, Department of Neurosurgery, Medellin, Colombia.
VI Dartmouth Hitchcock Medical Center, Department of Medicine (Section of Hematology/Oncology) and Neurology, Lebanon, New Hampshire, USA.
Read
1526
Timeswas read the article
648
Total PDF
878
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 125 | 63 | 188 |
| 2025 11 | 125 | 106 | 231 |
| 2025 10 | 50 | 36 | 86 |
| 2025 9 | 57 | 45 | 102 |
| 2025 8 | 66 | 26 | 92 |
| 2025 7 | 59 | 12 | 71 |
| 2025 6 | 35 | 4 | 39 |
| 2025 5 | 22 | 11 | 33 |
| 2025 4 | 9 | 5 | 14 |
| 2025 3 | 20 | 5 | 25 |
| 2025 2 | 11 | 6 | 17 |
| 2025 1 | 15 | 5 | 20 |
| 2024 12 | 10 | 5 | 15 |
| 2024 11 | 34 | 18 | 52 |
| 2024 10 | 22 | 34 | 56 |
| 2024 9 | 20 | 21 | 41 |
| 2024 8 | 18 | 20 | 38 |
| 2024 7 | 16 | 21 | 37 |
| 2024 6 | 15 | 6 | 21 |
| 2024 5 | 15 | 14 | 29 |
| 2024 4 | 14 | 21 | 35 |
| 2024 3 | 17 | 12 | 29 |
| 2024 2 | 18 | 14 | 32 |
| 2024 1 | 8 | 10 | 18 |
| 2023 12 | 8 | 16 | 24 |
| 2023 11 | 12 | 16 | 28 |
| 2023 10 | 13 | 34 | 47 |
| 2023 9 | 13 | 24 | 37 |
| 2023 8 | 7 | 7 | 14 |
| 2023 7 | 8 | 20 | 28 |
| 2023 6 | 8 | 4 | 12 |
| 2023 5 | 1 | 1 | 2 |
| 2023 4 | 1 | 3 | 4 |
| 2023 3 | 1 | 1 | 2 |
| 2023 2 | 1 | 0 | 1 |
| 2023 1 | 3 | 1 | 4 |
| 2022 12 | 1 | 1 | 2 |
Show all
